Table 1. Clinical characteristics of the study cohort.
| N | 50 |
|---|---|
| Age, years, median | 64.5 |
| Gender | |
| Male | 24 (48%) |
| Female | 26 (52%) |
| Type of malignancy | |
| Breast | 12 (24%) |
| Lung | 8 (16%) |
| Gastrointestinal | 21 (42%) |
| Genitourinary | 3 (6%) |
| Haematologic | 6 (12%) |
| Types of treatment | |
| Chemotherapy | 20 (40%) |
| Immunotherapy | 6 (12%) |
| Chemotherapy + immunotherapy | 5 (10%) |
| Chemotherapy + anti VEGF | 5 (10%) |
| Anti CD20 | 2 (4%) |
| Anti CD38 + proteasome inhibitor | 2 (4%) |
| Anti HER-2 | 3 (6%) |
| Chemotherapy + anti HER-2 | 2 (4%) |
| Endocrine + CDK4/6 inhibitor | 1 (2%) |
| Anti EGFR | 1 (2%) |
| Chemotherapy + anti EGFR | 2 (4%) |
| Bispecific T cell engager | 1 (2%) |
| Pre-vaccine COVID infection | |
| No | 43 (86%) |
| Yes | 7 (14%) |
| Vaccine information | |
| One dose | 14 (28%) |
| Two doses | 36 (72%) |
| Days between last dose and IgG measurement, median | 20 |
VEGF: vascular endothelial growth factor; HER: human epidermal growth factor receptor; CDK: cyclin-dependent kinase;
EGFR: epidermal growth factor receptor